Citi Pharma Plans Rs1–2 Billion IPO for Veterinary Subsidiary

Citi Pharma Expands into Veterinary and Real Estate Sectors

Citi Pharma Limited, one of Pakistan’s leading pharmaceutical companies, has announced plans to launch an initial public offering (IPO) for its wholly owned subsidiary, Citi Veterinary Pharma Limited (CVPL). The company disclosed the development in a notice to the Pakistan Stock Exchange (PSX), confirming that the IPO aims to raise between Rs1 and Rs2 billion.

CVPL has been established as a dedicated entity focused on manufacturing veterinary active pharmaceutical ingredients (APIs) and products for the local market. Citi Pharma’s Board of Directors has appointed K-Trade Securities Limited as the consultant to manage the issuance and listing process.

The company expects to generate approximately Rs1.5 billion in revenue through veterinary product trading in FY26, marking a significant milestone in its strategy to diversify revenue streams beyond human pharmaceuticals.

This move follows Citi Pharma’s recent entry into Pakistan’s real estate sector. The Securities and Exchange Commission of Pakistan (SECP) approved the establishment of Citi REIT Management Company (Private) Limited, a wholly owned subsidiary. Under this platform, the company plans three major real estate projects: one on Hali Road, Lahore; another on land at Khayaban-e-Zafar, Lahore; and a third near Islamabad International Airport.

By expanding into veterinary medicine and real estate, Citi Pharma is positioning itself as a diversified enterprise with multiple growth avenues. The IPO of CVPL not only strengthens its footprint in the pharmaceutical sector but also reflects a broader vision of sustainable revenue generation across industries.

This dual expansion highlights Citi Pharma’s ambition to balance healthcare innovation with strategic investments, ensuring long-term resilience in Pakistan’s evolving economic landscape.